UPDATE ON DRUG TRANSPORTER PROTEINS IN ACUTE MYELOID LEUKEMIA: PATHOLOGICAL IMPLICATION AND CLINICAL SETTING

Crit Rev Oncol Hematol. 2021 Mar 2:103281. doi: 10.1016/j.critrevonc.2021.103281. Online ahead of print.

ABSTRACT

Acute myeloid leukemia (AML) is one of the most common hematological neoplasia causing death worldwide. The long-term overall survival is unsatisfactory due to many factors including older age, genetic heterogeneity and molecular characteristics comprising additional mutations, and resistance to chemotherapeutic drugs. The expression of ABCB1/P-glycoprotein, ABCC1/MRP1, ABCG2/BCRP and LRP transporter proteins is considered the major reason for multidrug resistance (MDR) in AML, however conflicting data have been reported. Here, we review the main issues about drug transporter proteins in AML clinical scenario, and highlight the clinicopathological significance of MDR phenotype associated with ABCB1 polymorphisms and FLT3 mutation.

PMID:33667660 | DOI:10.1016/j.critrevonc.2021.103281